AA型淀粉样变性分期系统的开发与验证
基于Pavia(n=233)和Heidelberg(n=243)两个中心新诊断AA型淀粉样变性患者,通过ROC分析确定连续变量截断值,多变量模型筛选预后因素,开发并验证了预测总生存和肾衰竭的分期系统。年龄≥65岁、eGFR<45 ml/min/1.73 m²及利钠肽升高(BNP>130 ng/L和/或NT-proBNP>1000 ng/L)与总生存相关;蛋白尿>3 g/24h和eGFR<35 ml/min/1.73 m²预测肾衰竭进展。
要点
- 年龄≥65岁、eGFR<45及利钠肽升高是AA型淀粉样变性总生存的独立预后因素。
- 蛋白尿>3 g/24h和eGFR<35可识别进展至终末期肾衰竭的高危患者。
- 基于生物标志物的分期系统可简便地进行预后分层,类似AL和转甲状腺素蛋白淀粉样变性。
核心结论
- 研究识别并验证了基于生物标志物的AA型淀粉样变性总生存和肾衰竭分期系统。
研究设计与样本
- 多中心队列研究,测试队列来自Pavia(n=233),验证队列来自Heidelberg(n=243),纳入新诊断AA型淀粉样变性患者。
- 通过ROC分析确定预测24个月死亡或透析的连续变量截断值,多变量模型筛选预后因素。
主要发现
- 年龄≥65岁、eGFR<45 ml/min/1.73 m²及利钠肽升高(BNP>130 ng/L和/或NT-proBNP>1000 ng/L)与总生存相关,均赋简化系数1。
- 总生存分期系统评分越高,36个月平均总生存率越低:评分0–1为92%,评分2为72%,评分3为32%。
- 肾衰竭分期系统变量为蛋白尿>3 g/24h和eGFR<35 ml/min/1.73 m²,均赋简化系数1。
- 肾衰竭分期系统评分越高,36个月累积肾衰竭发生率越高:评分0为0%,评分1为24%,评分2为51%。
- 上述结果在验证队列中得到证实。
关键数值与推荐
- 总生存分期系统:年龄≥65岁、eGFR<45 ml/min/1.73 m²、BNP>130 ng/L和/或NT-proBNP>1000 ng/L,每项1分。
- 肾衰竭分期系统:蛋白尿>3 g/24h、eGFR<35 ml/min/1.73 m²,每项1分。
临床怎么用
- 临床可依据年龄、eGFR、利钠肽、蛋白尿等常规指标对AA型淀粉样变性患者进行预后分层。
- 分期系统有助于识别高死亡风险和高肾衰竭风险患者,指导随访和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m2, and N-terminal type-B natriuretic peptide >1000 ng/L and/or type-B natriuretic peptide >130 ng/L at diagnosis have poorer survival. Proteinuria >3.0 g/24 hours and eGFR <35 ml/min per 1.73 m2 identify patients at high risk of progression to end-stage kidney failure. Prognostic stratification in AA amyloidosis can be easily made by staging systems, similarly to AL and transthyretin amyloidosis. BACKGROUND: The kidney is involved in almost 100% of cases of AA amyloidosis, a rare disease caused by persistent inflammation with long overall survival but frequent progression to kidney failure. Identification of patients with advanced disease at diagnosis is difficult, given the absence of validated staging systems. METHODS: Patients with newly diagnosed AA amyloidosis from the Pavia (n=233, testing cohort) and Heidelberg (n=243, validation cohort) centers were included in this study. Cutoffs of continuous variables were determined by receiver operating characteristic analysis predicting death or dialysis at 24 months. Prognostic factors included in staging systems were identified by multivariable models in the testing cohort. RESULTS: Age ≥65 years, eGFR <45 ml/min per 1.73 m2, and elevated natriuretic peptides (type-B natriuretic peptide >130 ng/L and/or N-terminal type-B natriuretic peptide >1000 ng/L) were associated with overall survival and included in the staging system (all with simplified coefficients 1). Mean 36-month overall survival was lower with higher staging system scores (score 0–1: 92%; score 2: 72%; score 3: 32%). These results were confirmed in the validation cohort. For kidney failure, variables selected to enter in the staging system model were proteinuria >3 g/24 hour and eGFR <35 ml/min per 1.73 m2 (both with simplified coefficients 1). The 36-month cumulative incidence of kidney failure was higher with higher staging system scores (score 0: 0%; score 1: 24%; score 2: 51%). Again, similar results were obtained in validation cohort. CONCLUSIONS: We identified and validated biomarker-based staging systems for overall survival and kidney failure in AA amyloidosis.
引用
- Basset M, Schönland SO, Obici L, et al. Development and Validation of Staging Systems for AA Amyloidosis. J Am Soc Nephrol. 2024. PMID: 38512269. doi:10.1681/ASN.0000000000000339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。